<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364329">
  <stage>Registered</stage>
  <submitdate>28/05/2013</submitdate>
  <approvaldate>31/05/2013</approvaldate>
  <actrnumber>ACTRN12613000624785</actrnumber>
  <trial_identification>
    <studytitle>The effect of a formulated honey in type 2 diabetes</studytitle>
    <scientifictitle>The effects of a formulated honey with cinnamon, chromium and magnesium on glucose tolerance and insulin sensitivity in subjects with type 2 diabetes.</scientifictitle>
    <utrn>nil</utrn>
    <trialacronym>nil</trialacronym>
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This study aims to compare a formulated honey designed to deliver benefits to people with type 2 diabetes over and above the benefit of honey itself. To this end kanuka honey has been combined with cinnamon, chromium and magnesium to create a honey dietary supplement that may deliver positive effects on blood glucose and insulin levels. 15g of honey orally is administered daily for 40 days containing 200 micrograms chromium, 120mg magnesium and 1.5g cinnamon. Adherence will be monitored by returned amounts of honey at the end of 40days. There will be a 20 day washout period between treatments. </interventions>
    <comparator>Plain kanuka honey will be administered orally, 15g per day for 40 days. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Fasting glucose by serum assay</outcome>
      <timepoint>Baseline, 40 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Fasting insulin by serum assay</outcome>
      <timepoint>Baseline, 40 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood lipids by serum assay</outcome>
      <timepoint>Baseline, 40 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>HbA1c by serum assay</outcome>
      <timepoint>Baseline, 40 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes on metformin or no oral hypoglycaemic agents</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Sulphonylurea or insulin use
Medications that could affect glucose tolerance eg oral steroids
HbA1c level &gt; 80mmol/mol
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After the baseline visit the order in which the honeys will be administered will be randomised. Allocation will be done by sealed opaque envelope, sequentially numbered. </concealment>
    <sequence>Random sequence will be computer generated. </sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>masking cannot be used due to the colour and aroma of the cinnamon</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods>ANOVA for area under the curve glucose and insulin from baseline OGTT, then for differences between baseline and 40 days for all variables. A 2 arm crossover trial requires multiples of N=2 as there are 2 possible orders of treatment administration. Previous data on the variability of measurements of glucose tolerance and insulin sensitivity were used to calculate required sample size.  Calculations performed using a one-sample T-test and a 2 sided type-1 error rate of 5% revealed a sample size of 12 would be 90% powered to detect a clinically significant difference between the treatment groups. </statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2013</anticipatedstartdate>
    <actualstartdate>11/12/2013</actualstartdate>
    <anticipatedenddate>1/06/2014</anticipatedenddate>
    <actualenddate>11/04/2014</actualenddate>
    <samplesize>12</samplesize>
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Jeremy Krebs</primarysponsorname>
    <primarysponsoraddress>Private Bag 31907
Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Honeylab</fundingname>
      <fundingaddress>10 Sterling gate drive, bethlehem, tauranga 3110
</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study aims to compare a formulated honey designed to deliver benefits to people with type 2 diabetes over and above the benefit of honey itself. To this end kanuka honey has been combined with cinnamon, chromium and magnesium to create a honey dietary supplement that may deliver positive effects on blood glucose and insulin levels. This formulated honey will be compared with ordinary kanuka honey firstly in an oral glucose tolerance test for acute glucose and insulin response, then over 40 days in an intervention. </summary>
    <trialwebsite>nil</trialwebsite>
    <publication>Whitfield P, Parry-Strong A, Walsh E, Weatherall M, Krebs JD. The effect of a cinnamon, chromium and magnesium formulated honey on glycaemic control, weight loss and lipid parameters in Type 2 diabetes: An open-label cross-over randomised controlled trial.  European Journal of Nutrition 2015 on line DOI 10.1007/s00394-015-0926-x</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>nil</publicnotes>
    <ethicscommitee>
      <ethicname>Central Region Health and Disability Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6021
</ethicaddress>
      <ethicapprovaldate>20/08/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>4/06/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Jeremy Krebs</name>
      <address>Capital and Coast DHB
Private bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>jeremy.krebs@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Cecilia Ross</name>
      <address>Capital and Coast DHB
Private bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>cecilia.ross@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amber Parry Strong</name>
      <address>Capital and Coast DHB
Private bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>amber.parry-strong@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>